Coadministration has not been studied. St John’s Wort is an inducer and therefore can reduce cabotegravir exposure. Coadministration of rifampicin (600 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir AUC by 59% A similar effect is expected with St John’s Wort. Therefore, coadministration is contraindicated with intramuscular cabotegravir due to potential for loss of therapeutic effect and development of resistance. However, a recent study suggests a low risk of a clinically relevant pharmacokinetic interaction with low-hyperforin formulations (<1 mg/day) of St John’s Wort (hyperforin is the constituent responsible for induction of CYPs and P-gp). Coadministration may be considered with St John’s Wort formulations that clearly state the hyperforin content and which have a total daily hyperforin dose of 1 mg or less.